Zayden-Jung/endorphin-tabularium-docs
1
1
Fork 0
Code Issues Pull Requests 1 Actions Packages Projects Releases Wiki Activity

Audit biotech candidates and separate research milestones from revenue

Browse Source
This commit is contained in:
Codex Bot
2026-10-30 22:19:52 +08:00
parent fa09a01421
commit 3e7792191e
5 changed files with 392 additions and 9 deletions
Download Patch File Download Diff File Expand all files Collapse all files
content/research/ai-companies.seed.json
+384 -1
View File
@@ -1,5 +1,5 @@
{
"version": "2026-10-30-tc-finance-1",
"version": "2026-10-30-tc-biotech-1",
"asOf": "2026-10-30",
"scope": "全球公开资料研究：保留首批个案，并扩展核查2025—2026八个YC批次候选池；成立年份以官方公司页面字段为依据。",
"limitations": [
@@ -49626,6 +49626,215 @@
"kind": "公司官方资料",
"summary": "自述Founded 2024，链接zownhomes.com；说明买家补助由赚取佣金支持。",
"limitation": "地域、合作经纪及返佣后的净额分摊未核，不把员工档案或客户交易数当订阅数。"
},
{
"id": "TC25-BIO-LIST",
"companyId": null,
"title": "2025生物技术参赛名单登记",
"url": "https://techcrunch.com/2025/12/24/the-9-top-biotech-startups-from-disrupt-startup-battlefield/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "媒体名单读取",
"summary": "仅作为候选发现入口。",
"limitation": "参赛年不是成立年，业务和阶段另读原始资料；不把生物技术类别直接等同AI公司。"
},
{
"id": "TC25-BIO-CASNX-HOME",
"companyId": null,
"title": "CasNx器官工程研发",
"url": "https://www.casnx.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "在体外供体器官上研发CRISPR处理，官网链接科学出版物及研究合作入口。",
"limitation": "研究论文、合作和未来器官疗法不当商业收入或获批产品；当前AI核心角色未专项核实。"
},
{
"id": "TC25-BIO-CASNX-YEAR",
"companyId": null,
"title": "UF孵化方CasNx沿革",
"url": "https://innovate.research.ufl.edu/uf-researchers-rewriting-organ-biology-with-revolutionary-transplant-technology/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "大学孵化机构原始介绍",
"summary": "UF Innovate 2025-08-19介绍其客户公司CasNx于2024年成立。",
"limitation": "机构介绍不是精确注册核验；基础研究与公司能力、未来临床价值及收入分开。"
},
{
"id": "TC25-BIO-CHIPIRON-HOME",
"companyId": null,
"title": "Chipiron MRI与历史里程碑",
"url": "https://www.chipiron.co/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "研发超低场MRI，官网自述AI降噪及图像重建，并列2023—2024技术和融资沿革。",
"limitation": "2026—2028验证、临床与FDA路线图是计划；截至研究日不当已经完成审批。融资、补助不作收入，设备与软件持续收费需拆分。"
},
{
"id": "TC25-BIO-EXACTICS-HOME",
"companyId": null,
"title": "Exactics诊断产品",
"url": "https://www.exacticsbiotech.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "研发家庭诊断工具，官网列原型、团队和大学合作。",
"limitation": "专利、融资、市场规模与产品研发不是收入；未确认当前AI核心交付或临床性能，不与同名模具企业合并。"
},
{
"id": "TC25-BIO-EXACTICS-YEAR",
"companyId": null,
"title": "Exactics公司公开主页",
"url": "https://www.linkedin.com/company/exactics",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "自述Founded 2021，链接exacticsbiotech.com。",
"limitation": "精确注册日未核；老About链接现跳转团队页，不把旧检索内容当当前全文。"
},
{
"id": "TC25-BIO-AVARA-ACCESS",
"companyId": null,
"title": "Avara官网访问缺项",
"url": "https://avarabio.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官网访问缺项",
"summary": "当前仅取得wellness device标题，正文不可读。",
"limitation": "不据标题确认完整功能、AI作用、销量或医疗验证。"
},
{
"id": "TC25-BIO-AVARA-TERMS-ACCESS",
"companyId": null,
"title": "Avara运营者线索与访问缺项",
"url": "https://avarabio.com/terms",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方条款访问缺项",
"summary": "检索可见Lumos Strategies OÜ运营者线索，直达正文为空。",
"limitation": "未将检索摘录当已读条款，需补可读主体链接与AI交付；条款更新日期不是成立年。"
},
{
"id": "TC25-BIO-LUMOS-REGISTRY",
"companyId": null,
"title": "Lumos Strategies同名官方登记",
"url": "https://ariregister.rik.ee/eng/company/17138613",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "官方公司登记",
"summary": "爱沙尼亚官方登记列Lumos Strategies OÜ注册于2024-12-19，登记号17138613。",
"limitation": "登记可读，但Avara条款正文空白，尚未以可读官网或登记号完成产品—运营者对应；不按名称直接合并主体，未解读删除公告为已注销。"
},
{
"id": "TC25-BIO-MIRAQULES-HOME",
"companyId": null,
"title": "Miraqules止血材料及沿革",
"url": "https://www.miraqules.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "官方介绍止血生物材料及StopBleed，自述2018年起步。",
"limitation": "当前页夹有模板内容；不当AI模型或临床独立验证，效果倍数、获资助与市场不作收入。"
},
{
"id": "TC25-BIO-NEPHROGEN-HOME",
"companyId": null,
"title": "Nephrogen AI筛选研发",
"url": "https://www.nephrogenbiotech.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "自述AI结合高通量筛选，研发肾脏与胰腺基因递送载体，官网列科研出版物。",
"limitation": "体外/动物或组织研究不等获批治疗；性能倍数、药企赞助和合作资金不自动等ARR，旧研究及顾问履历与公司交付分开。"
},
{
"id": "TC25-BIO-NEPHROGEN-YC",
"companyId": null,
"title": "Nephrogen机构年份与批次",
"url": "https://www.ycombinator.com/companies/nephrogen",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "投资孵化机构名录",
"summary": "YC列Founded 2022、Summer 2020，当前域名一致。",
"limitation": "年份与批次时序不一致，精确成立链待核；两项均早于2025，不根据2025参赛新增公司。"
},
{
"id": "TC25-BIO-PRAXISPRO-HOME",
"companyId": null,
"title": "PraxisPro生命科学商业团队软件",
"url": "https://www.praxispro.ai/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "为药企及器械团队提供AI角色扮演、准备度认证和教练工作流。",
"limitation": "客户培训收益和药品销售不是公司收入；不因生命科学买家归药物研发模型，合规及效果宣传未独立核。"
},
{
"id": "TC25-BIO-PRAXISPRO-YEAR",
"companyId": null,
"title": "PraxisPro公司公开主页",
"url": "https://www.linkedin.com/company/praxispro-ai",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "自述Founded 2023，域名praxispro.ai对应，主营商业团队智能。",
"limitation": "公司自述而非精确登记；模型专用宣传不等独立能力验证，团队范围不填精确人数。"
},
{
"id": "TC25-BIO-REMED-HOME",
"companyId": null,
"title": "Reme-D诊断试剂",
"url": "https://reme-d-inc.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "研发及制造人和动物疾病分子诊断、核酸提取及检测工具。",
"limitation": "未核AI核心交付；试剂销售、仪器和研究服务收费需拆分，检测人数或社会效益不等收入。"
},
{
"id": "TC25-BIO-REMED-HISTORY",
"companyId": null,
"title": "Reme-D早期官方业务记录",
"url": "https://reme-d-inc.com/reme-d-is-a-winner-in-the-falling-walls-science-venture/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "官网记Science Summit 2024的Reme-D业务获奖活动。",
"limitation": "仅证明更早业务沿革，不当精确注册、临床获批或独立性能验证。"
},
{
"id": "TC25-BIO-REMED-YEAR-ACCESS",
"companyId": null,
"title": "Reme-D机构年份读取缺项",
"url": "https://jobs.techstars.com/companies/reme-d",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "机构原始资料访问缺项",
"summary": "检索有2022成立线索，直达Cache miss。",
"limitation": "不当完整机构页已读，精确注册及不同地区主体链留缺；范围外以官方2024业务材料补证。"
},
{
"id": "TC25-BIO-SURGICURE-HOME",
"companyId": null,
"title": "Surgicure医疗器械",
"url": "https://www.surgicuretech.com/",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "公司官方资料",
"summary": "HORSESHOE气管导管固定器械，官网列Surgicure Technologies, Inc.。",
"limitation": "当前AI核心角色未确认；医院避免损失、ROI估计及安全宣传不等公司收入，不能从专利或Demo推独立临床效果。"
},
{
"id": "TC25-BIO-SURGICURE-SEC",
"companyId": null,
"title": "Surgicure原始发行申报",
"url": "https://www.sec.gov/Archives/edgar/data/2038291/000203829124000004/xslFormDX08/primary_doc.xml",
"publishedAt": null,
"accessedAt": "2026-10-30",
"kind": "监管原始申报",
"summary": "发行人Surgicure Technologies, Inc.申报Delaware、2019年组织成立，CIK2038291。",
"limitation": "发行人自报、未经SEC独立审核；不是募资等于经营收入，不能与英国同名医疗公司合并。"
}
],
"reviews": [
@@ -51751,6 +51960,35 @@
"TC25-FIN-ZOWN-YEAR"
],
"handling": "当前官网业务优先于旧描述，订阅、结果收费、地产经纪和AI辅助人工服务分开。标价、ACME演示财务、贷款、存款、房产估值、客户收入和返佣不导入公司ARR；访问失败保留缺项。"
},
{
"id": "TC25-BIO-R-SCOPE",
"type": "生物技术名单、研发与收入边界",
"company": "2025生物技术参赛候选",
"scope": "excluded-candidate",
"summary": "逐项登记9项：8项范围外/既有业务，1项主体对应待核；没有新增主公司或收入。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-CASNX-HOME",
"TC25-BIO-CASNX-YEAR",
"TC25-BIO-CHIPIRON-HOME",
"TC25-BIO-EXACTICS-HOME",
"TC25-BIO-EXACTICS-YEAR",
"TC25-BIO-AVARA-ACCESS",
"TC25-BIO-AVARA-TERMS-ACCESS",
"TC25-BIO-LUMOS-REGISTRY",
"TC25-BIO-MIRAQULES-HOME",
"TC25-BIO-NEPHROGEN-HOME",
"TC25-BIO-NEPHROGEN-YC",
"TC25-BIO-PRAXISPRO-HOME",
"TC25-BIO-PRAXISPRO-YEAR",
"TC25-BIO-REMED-HOME",
"TC25-BIO-REMED-HISTORY",
"TC25-BIO-REMED-YEAR-ACCESS",
"TC25-BIO-SURGICURE-HOME",
"TC25-BIO-SURGICURE-SEC"
],
"handling": "生物技术不直接等AI；治疗、医疗硬件、试剂及商业培训软件按交付分开。论文、临床计划、审批目标、专利、融资、赞助及客户ROI不作已实现ARR或独立验证。Nephrogen批次冲突、Avara空白条款与同名登记、REME-D机构访问缺项保留。"
}
],
"coverage": {
@@ -53812,6 +54050,151 @@
]
}
]
},
{
"id": "TC-2025-battlefield-biotech-1",
"sourceId": "S02",
"url": "https://techcrunch.com/2025/12/24/the-9-top-biotech-startups-from-disrupt-startup-battlefield/",
"accessedAt": "2026-10-30",
"scope": "本篇9项文字标题均登记并逐项尝试原始官网，8项有研究年份之前的公司或业务资料，Avara/Lumos主体对应待核；逐项保留AI作用、研发阶段、不可读及收入缺项，不等全部参赛者或两年档案。",
"complete": false,
"records": [
{
"id": "TC25-BIO-01",
"name": "CasNx",
"url": "https://www.casnx.com/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "孵化方资料列2024成立，按范围外保留；CRISPR研究不直接认定AI业务或已获批疗法。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-CASNX-HOME",
"TC25-BIO-CASNX-YEAR"
]
},
{
"id": "TC25-BIO-02",
"name": "Chipiron",
"url": "https://www.chipiron.co/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "官网有2025前业务里程碑，非本轮新公司；属于医疗成像硬件中的AI，未来审批和商业化计划不当当前交付或ARR。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-CHIPIRON-HOME"
]
},
{
"id": "TC25-BIO-03",
"name": "Exactics",
"url": "https://www.exacticsbiotech.com/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "同域名公司主页列2021成立，按既有公司排除；快速诊断不直接当AI或经常性软件收入。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-EXACTICS-HOME",
"TC25-BIO-EXACTICS-YEAR"
]
},
{
"id": "TC25-BIO-04",
"name": "Lumos Strategies OÜ / Avara",
"url": "https://avarabio.com/",
"categoryId": "C00",
"kind": "company",
"profileStatus": "unavailable",
"status": "pending-year",
"note": "同名主体登记2024可读，但Avara官网及条款正文为空；产品、运营者登记号与AI作用未闭合，保留主体/年份核查，不新增公司。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-AVARA-ACCESS",
"TC25-BIO-AVARA-TERMS-ACCESS",
"TC25-BIO-LUMOS-REGISTRY"
]
},
{
"id": "TC25-BIO-05",
"name": "Miraqules",
"url": "https://www.miraqules.com/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "官网列2018起步，按既有业务排除；止血材料不能仅据生物技术类别归AI公司，模板内容及临床宣传未独立核。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-MIRAQULES-HOME"
]
},
{
"id": "TC25-BIO-06",
"name": "Nephrogen",
"url": "https://www.nephrogenbiotech.com/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "YC成立2022与S2020批次时序冲突保留，但均早于研究年份；AI用于生物递送研发，赞助和未来治疗价值不作经常性软件收入。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-NEPHROGEN-HOME",
"TC25-BIO-NEPHROGEN-YC"
]
},
{
"id": "TC25-BIO-07",
"name": "PraxisPro",
"url": "https://www.praxispro.ai/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "公司页列2023成立；按实际任务归生命科学专业商业软件，不视为新药研发或基础模型，不与其他Praxis同名公司合并。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-PRAXISPRO-HOME",
"TC25-BIO-PRAXISPRO-YEAR"
]
},
{
"id": "TC25-BIO-08",
"name": "Reme-D",
"url": "https://reme-d-inc.com/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "官网2024活动证明更早业务，按既有业务排除；机构年份直达失败留缺，AI用途和试剂/设备收入拆分未知。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-REMED-HOME",
"TC25-BIO-REMED-HISTORY",
"TC25-BIO-REMED-YEAR-ACCESS"
]
},
{
"id": "TC25-BIO-09",
"name": "Surgicure Technologies",
"url": "https://www.surgicuretech.com/",
"categoryId": "C07",
"kind": "company",
"profileStatus": "readable",
"status": "outside-cohort",
"note": "原始SEC申报列2019组织成立，排除新公司；气道固定器械不直接认定AI公司，融资、客户ROI与收入分开。",
"evidenceIds": [
"TC25-BIO-LIST",
"TC25-BIO-SURGICURE-HOME",
"TC25-BIO-SURGICURE-SEC"
]
}
]
}
],
"directoryRechecks": [
content/research/ai-companies.sources.json
+3 -3
View File
@@ -1,5 +1,5 @@
{
"version": "2026-10-30-34",
"version": "2026-10-30-35",
"scopeConfirmedAt": "2026-10-30",
"acceptance": "以确认的公开来源清单为边界，逐条核对并标明缺项。",
"provenance": "S01—S12恢复自已提交用户的《AI公司研究_来源与分类模板》来源清单；S13—S16单列后续已使用的补充证据渠道，不将使用次数当作全量覆盖。",
@@ -28,8 +28,8 @@
"techcrunch.com"
],
"initialAccess": "AI栏目可读取",
"boundary": "2026首页定向3项已登记，另从AI第3—4页登记5项：3项关联公司、1项范围外、1项待核；不等全部卡片核验。另已读2025年度档案入口与AI第二页，并完整登记一篇2025企业竞赛名单32项：复用1项、范围外29项、待核2项；每项均尝试原始链接，未知与不可读保留。单篇32项不等全部200参赛者、全部分页或两年全量；RSS/API普通请求受限。 另从AI第5—6页定向4项：2项原始资料归范围外，2项原始成立/年份待核；不是全部卡片、参赛者或档案。 另逐条登记2025政府/法律名单正文11项（标题称10）：7项范围外或既有业务、4项成立/主体待核；不新增主公司或ARR，非全部200或两年档案。 另将2025金融/地产名单14项全部登记：11项范围外/既有业务，3项年份/主体/AI待核；不新增公司或收入，不等其余竞赛类别。",
"nextCheck": "继续核本篇2项的成立、主体及AI主营，优先解决Billow批次与发现年份时序、Sponstar原始年份冲突；既有业务的法律沿革及不可读项仍留缺；沿普通2025档案和AI分页扩展其余来源台账，区分参赛年、批次与公司成立年。 继续核Laplace原始年份及Eka精确注册主体；Recursive的2025/2026年份冲突保留。 继续核Honeyjar主字段与转载的年份差异、Blueprints原始可读资料与旧建筑业务主体；不把包价、演示金额或建设项目价值当ARR。 本篇待核Aparti原始成立、JustiGuide的2024/2026语义、orchestraos主体与年份及Pytho原始登记；补其余竞赛类别和年度档案，不用同名链接替代核查。 补ticker原始可读页面、Investwise主营及主体、Soundspace成立与AI实际交付；保留Genia结果收费与首页套餐的合同缺项，不把交易、返佣或客户资产年化为ARR。",
"boundary": "2026首页定向3项已登记，另从AI第3—4页登记5项：3项关联公司、1项范围外、1项待核；不等全部卡片核验。另已读2025年度档案入口与AI第二页，并完整登记一篇2025企业竞赛名单32项：复用1项、范围外29项、待核2项；每项均尝试原始链接，未知与不可读保留。单篇32项不等全部200参赛者、全部分页或两年全量；RSS/API普通请求受限。 另从AI第5—6页定向4项：2项原始资料归范围外，2项原始成立/年份待核；不是全部卡片、参赛者或档案。 另逐条登记2025政府/法律名单正文11项（标题称10）：7项范围外或既有业务、4项成立/主体待核；不新增主公司或ARR，非全部200或两年档案。 另将2025金融/地产名单14项全部登记：11项范围外/既有业务，3项年份/主体/AI待核；不新增公司或收入，不等其余竞赛类别。 另将2025生物技术名单9项全部登记：8项范围外或既有业务，1项产品与主体对应待核；不新增公司或收入，非全部竞赛类别。",
"nextCheck": "继续核本篇2项的成立、主体及AI主营，优先解决Billow批次与发现年份时序、Sponstar原始年份冲突；既有业务的法律沿革及不可读项仍留缺；沿普通2025档案和AI分页扩展其余来源台账，区分参赛年、批次与公司成立年。 继续核Laplace原始年份及Eka精确注册主体；Recursive的2025/2026年份冲突保留。 继续核Honeyjar主字段与转载的年份差异、Blueprints原始可读资料与旧建筑业务主体；不把包价、演示金额或建设项目价值当ARR。 本篇待核Aparti原始成立、JustiGuide的2024/2026语义、orchestraos主体与年份及Pytho原始登记；补其余竞赛类别和年度档案，不用同名链接替代核查。 补ticker原始可读页面、Investwise主营及主体、Soundspace成立与AI实际交付；保留Genia结果收费与首页套餐的合同缺项，不把交易、返佣或客户资产年化为ARR。 补Avara可读条款和Lumos登记号对应、其他生物技术候选的AI实际作用及地域主体链；研发、临床、审批计划和药企赞助与当前商业收入分开。",
"limitation": "需追溯原始披露，部分文章受访问限制",
"accessRecheckedAt": "2026-10-30"
},
content/research/ai-income-analysis.json
+1 -1
View File
@@ -1,5 +1,5 @@
{
"sourceVersion": "2026-10-30-tc-finance-1",
"sourceVersion": "2026-10-30-tc-biotech-1",
"asOf": "2026-10-30",
"metric": "platform-mrr-usd",
"sampleUnit": "product-or-business",